Ocuphire Pharma Investor Update

RM 12 Nyxol Has Potential To Be The Only Option For RM Physicians AVOID Use of Cholinergic Agonists (Pilocarpine) Due to Safety Risk on Ciliary Muscle 2 Classes of Mydriatic Agents Phenylephrine (a1 agonist) Sympathetic (primarily a1) innervation stimulates the iris dilator muscles Tropicamide (anti-cholinergic) Parasympathetic innervation stimulates the iris sphincter and ciliary muscle Lens Cornea Pupil Iris Ciliary muscle Reversal via the Ciliary Muscle by Cholinergic Agonists* is Not a 'Safe' Option 1 Pilocarpine FDA Label (2017) 2. Optician (2012)- Mydriatic Drugs: Practical Considerations 3. Lee DA, Higginbotham EJ, 2005. Glaucoma and its treatment: a review. Am J Health Syst Pharm 62, 691-699. X X X Retinal tear has been reported in some patients, especially high myopes¹ Induces accommodation spasm and reduction in distance vision² Induced anterior shift of the lens can increase the risk of acute angle-closure glaucoma² X High incidence of brow ache and headache following installation³ * Cholinergic Agonists include pilocarpine, carbachol, and aceclidine. Note, pilocarpine is rarely used off-label for RM given these safety concerns. Nyxol® is the only eye drop in clinical development for multiple indications with a MOA that does not affect the ciliary muscle Ocuphire PHARMA

View entire presentation